Share  |  Print  |  A A A
Home
To share a link to this page with a friend, colleague, or family member, please complete the form below:

Please complete both e-mail fields with valid addresses.




E-mail addresses entered on this page will be used solely for the purpose of sending an e-card. Endo Pharmaceuticals and companies working with Endo Pharmaceuticals will not share your personal and medical information with any third parties, such as outside mailing lists. To remove yourself from future contact from Endo Pharmaceuticals, e-mail the .
Privacy/Legal
Thank you for sending an e-card about OPANA.com. Your e-card has been sent and the recipient(s) should receive an e-mail notification shortly.

Close
  • Think OPANA ER for your appropriate patients with moderate to severe chronic pain
  • No known CYP450 PK drug-drug interactions at clinically relevant doses1
  • True 12-hour dosing that lasts2
  • Widely available on managed care plans (including Medicare Part D) for 8 out of 10
    covered patients3
  • Think OPANA for your appropriate patients with moderate to severe acute pain
  • No known CYP450 PK drug-drug interactions at clinically relevant doses4
  • Long 7 to 9 hour half-life5
Select

Hydrocodone

Methadone

Morphine

Oxycodone

Oxymorphone


References

  1. OPANA ER Full Prescribing Information. Chadds Ford, Pa: Endo Pharmaceuticals; 2008.
  2. Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy. 2004;24(4):468-476.
  3. MediMedia Formulary Compass. http://www.formularycompass.com. Accessed December 31, 2008.
  4. OPANA Full Prescribing Information. Chadds Ford, Pa: Endo Pharmaceuticals; 2006.
  5. Adams MP, Ahdieh H. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D. 2005;6(2):91-99.